HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.
Kristen Lee Moriarty, Speaker at Immunology Conferences
UCONN Health, United States
Title : Nirmatrelvir-Ritonavir Counseling and Acceptance in Pregnancy


The National Institute of Health recommends Nirmatrelvir-Ritonavir (NIR) treatment for pregnant patients with COVID-19. However, little is known about NIR treatment acceptance rates in pregnant patients and what strategies may increase access and acceptance rates of NIR treatment. In April 2022, an NIR access program was started at our institution to offer standardized counseling and access to NIR treatment for all COVID-19-positive pregnant patients who were eligible for treatment. The access program included a standardized workflow with a high-risk nurse triaging and determining eligibility for NIR treatment in COVID-19 positive pregnant patients and a telehealth visit with a Maternal Fetal Medicine subspecialist that same day to review and offer NIR treatment. We observed a 58.3% acceptance rate for NIR treatment in our cohort (n=36). Patients who accepted NIR treatment had lower gravidity and were more likely to have the symptom of myalgia from their COVID-19 infection than those who did not accept NIR treatment. Patients who accepted NIR treatment also were more likely to be SARS-CoV-2 vaccinated although the difference (81% versus 60%) was not statistically significant (p=0.260). We did not observe any significant differences in neonatal outcomes. NIR access programs should be considered to increase access and acceptance of NIR treatment during pregnancy, and future studies with larger sample sizes should explore maternal and neonatal outcomes with NIR access programs in place.

Audience Take Away:

  • Potential for adverse maternal-fetal outcomes with COVID-19 infection
  • Importance of COVID-19 vaccination in pregnancy populations and use of paxlovid
  • Increased awareness for provider counseling and instructions with Paxlovid use in pregnant populations
  • Formation of formal Paxlovid counseling programs to help standardize patient education and access


Dr. Moriarty studied Chemistry at La Salle University, Philadelphia and graduated Maxima Cum Laude in 2014. She attended medical school at Drexel University College of Medicine (DUCOM). At DUCOM, she further advanced her teaching skills as a Chemistry and Organic Chemistry tutor, Anatomy Scholar tutor, and multidisciplinary Academic Coach. She completed her Obstetrics and Gynecology Residency at the University of Connecticut Health where she served as Administrative Chief Resident. She has worked on several research projects, presented at various regional meetings, and published one of her projects in a high-impact journal, Placenta. She received the Dr. James Egan Award for Outstanding Obstetric Research Project in 2022.